Yale Urology hosted the 2nd Annual Transpacific Asian American Cancer Consortium (TPAACC), April 29-30, 2025. The consortium brings together urologic oncologists from all over the country and East Asia.
The group was formed in 2024 by Isaac Yi Kim, MD, PhD, MBA, chair of Yale School of Medicine’s Department of Urology and chief of urology at Yale New Haven Health. He and other members hope to collaborate more and innovate practice-changing clinical trials. Their goal is to launch a multi-center study later this year.
Proposed trials include:
- Neoadjuvant Pembrolizumab plus Axitinib in Renal Cell Carcinoma Patients with Venous Tumor Thrombus Extension
- Effect of 5-ARI on Tumor Recurrence in Non-Muscle Invasive Bladder Cancer
Clinical trial challenges and the state of research funding in Indonesia were also discussed. Kim wrapped up the meeting portion with an update on his SIMCAP project, a randomized trial that hopes to assess the clinical benefit of combining radical surgery with systemic therapy in men with newly diagnosed metastatic prostate cancer.
The group ended their time at Yale with a walking tour of campus, thanks to the Office of International Affairs and Visitor Center.